highperformr logo

Kiadis Pharma's Overview

Total employees0
HeadquartersAmsterdam
Founded1997

Kiadis Pharma was a clinical-stage biopharmaceutical company that specialized in the development of innovative cell-based immunotherapies for patients with life-threatening diseases, primarily focusing on cancer. Its core technology centered around natural killer (NK) cells, aiming to provide 'off-the-shelf' treatments. Key programs included K-NK002 for hematopoietic stem cell transplant relapse and K-NK003 for relapsed/refractory acute myeloid leukemia. In April 2021, Sanofi successfully completed the acquisition of Kiadis Pharma, integrating its NK cell technology platform and pipeline to strengthen Sanofi's immuno-oncology portfolio.

Where is Kiadis Pharma's Headquarters?

HQ Function

Served as the central hub for research and development, corporate operations, and clinical trial management prior to its acquisition by Sanofi.

Notable Features:

Located within the Amsterdam Science Park, a vibrant ecosystem fostering collaboration between academia, research institutes, and innovative companies.

Work Culture:

As a clinical-stage biotech, the culture was likely characterized by innovation, scientific rigor, a fast-paced environment, and a strong focus on patient outcomes. Collaboration and adaptability would have been key.

HQ Significance:

The Amsterdam headquarters was pivotal for Kiadis's development of its NK cell platform and advancing its clinical programs towards potential commercialization.

Values Reflected in HQ: The location within a science park likely reflected values of innovation, scientific excellence, and collaboration. The company's mission demonstrated a commitment to addressing unmet medical needs.

Location:

Prior to its acquisition by Sanofi, Kiadis Pharma's global presence was primarily driven by its clinical trial operations, which spanned multiple countries in Europe and North America. The company also engaged in global collaborations and partnerships. Following the acquisition, Kiadis's technology and assets became part of Sanofi's extensive global R&D, manufacturing, and commercial network, significantly expanding the potential reach of its NK cell platform.

Street Address:

Science Park 406

City:

Amsterdam

State/Province:

North Holland

Country:

Netherlands

Kiadis Pharma's Global Presence

Cambridge, MA, USA

Address: Undisclosed (Likely a small presence for US operations/partnerships)

To facilitate engagement with the U.S. Food and Drug Administration (FDA), access to U.S. clinical trial sites, and interaction with the North American investment community and potential pharmaceutical partners.

Buying Intent Signals for Kiadis Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Kiadis Pharma

As of April 2025, Kiadis Pharma' leadership includes:

Arthur Lahr - Former Chief Executive Officer
Michel Streuli - Former Chief Financial Officer
Anke Kretz-Rommel - Former Chief Scientific Officer
Andrew Sandler - Former Chief Medical Officer

Investors of Kiadis Pharma

Kiadis Pharma has been backed by several prominent investors over the years, including:

Life Sciences Partners (LSP)
Van Herk Ventures
Draper Esprit
BioGeneration Ventures (BGV)
Various public shareholders (Euronext Amsterdam and Brussels)

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits4

With the completion of Sanofi's acquisition of Kiadis Pharma in April 2021, the existing Kiadis Pharma executive team was dissolved as the company's operations and personnel were integrated into Sanofi. Key leadership roles transitioned as part of this integration.

Departures

Arthur Lahr, Departed post-acquisition by Sanofi.
Michel Streuli, Departed post-acquisition by Sanofi.

New Appointments:

N/A, Following the acquisition by Sanofi, Kiadis Pharma ceased to operate as an independent entity, and its leadership was integrated or transitioned out. No new appointments were made to a standalone Kiadis executive team.

Technology (Tech Stack) used by Kiadis Pharma

Discover the tools Kiadis Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Kiadis Pharma Email Formats and Examples

Prior to its acquisition by Sanofi, Kiadis Pharma likely used common corporate email formats. Based on typical naming conventions, the most probable formats would have been [first_initial][last]@kiadis.com or [first].[last]@kiadis.com. These email addresses are no longer active.

f[last]@kiadis.com (e.g., jdoe@kiadis.com) or [first].[last]@kiadis.com (e.g., jane.doe@kiadis.com)

Format

a.lahr@kiadis.com (Hypothetical example based on former CEO and common format)

Example

0%

Success rate

News and media

Sanofi Press ReleaseApril 16, 2021

Sanofi completes acquisition of Kiadis

Sanofi announced today the successful completion of its acquisition of Kiadis Pharma N.V. (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative ‘off-the-shelf’ natural killer (NK) cell-based medicines for the treatment of patients with life-threatening diseases. Kiadis’ proprietary platform is based on allogeneic NK cells from a healthy donor....more

Kiadis Pharma Press Release (Archived/Reported)December 18, 2020

Kiadis shareholders approve Sanofi's recommended all-cash public offer

Kiadis Pharma N.V. announced that during the extraordinary general meeting of shareholders (EGM) held today, Kiadis shareholders approved the acquisition of Kiadis by Sanofi. This paved the way for Sanofi's acquisition of the company....more

Sanofi Press ReleaseNovember 2, 2020

Sanofi to acquire Kiadis, a clinical-stage company developing next generation NK cell therapies

Sanofi announced it would acquire Kiadis for €5.45 per share, valuing the company at approximately €308 million. The acquisition aimed to bolster Sanofi's immuno-oncology pipeline with Kiadis's NK cell technology platform....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Kiadis Pharma, are just a search away.